Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits

Tumba, Nancy; Owen, Gavin R.; Killick, Mark; Papathanasopoulos, Maria A.

doi:10.1016/j.jvacx.2022.100222

Cited by 3 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…i.e. SOSIPs 13 . Currently, HVTN 302 phase 1 clinical trial (NCT05217641) is evaluating safety and immunogenicity of the stabilized HIV Env trimers delivered as mRNA (Table 1 ).…”

Section: The Landscape Of B Cell-targeted Vaccinesmentioning

confidence: 99%

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report

Maciel,

Amara,

Bar

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), convened a virtual workshop on August 8-9 th , 2023 to explore potential synergies between HIV vaccine approaches that are designed to induce cellular or humoral immune responses. The goal of this workshop was to review data on leading vaccine candidates and to discuss the best strategies for combining these approaches to optimize immunity against HIV. Here, we summarize the findings reviewed at the workshop and discuss the knowledge gaps and priorities for future studies that will help accelerate the development of a preventive HIV vaccine.

show abstract

“…i.e. SOSIPs 13 . Currently, HVTN 302 phase 1 clinical trial (NCT05217641) is evaluating safety and immunogenicity of the stabilized HIV Env trimers delivered as mRNA (Table 1 ).…”

Section: The Landscape Of B Cell-targeted Vaccinesmentioning

confidence: 99%

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report

Maciel,

Amara,

Bar

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

show abstract

Production and Study of Immunochemical Properties of Stabilized Env Trimer of Recombinant Form CRF63_02A6 of HIV-1

Rudometova,

Rudometov,

Fando

et al. 2023

Bull Exp Biol Med

View full text Add to dashboard Cite

mRNA-based HIV-1 vaccines

Ahmed,

Herschhorn

2024

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY The success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to fight other infectious agents. HIV-1 is a lentivirus that integrates into the host cell genome and persists for the lifetime of infected cells. Multiple mechanisms of immune evasion have posed significant obstacles to the development of an effective HIV-1 vaccine over the last four decades since the identification of HIV-1. Recently, attempts to address some of these challenges have led to multiple studies that manufactured, optimized, and tested, in different animal models, mRNA-based HIV-1 vaccines. Several clinical trials have also been initiated or are planned to start soon. Here, we review the current strategies applied to HIV-1 mRNA vaccines, discuss different targeting approaches, summarize the latest findings, and offer insights into the challenges and future of HIV-1 mRNA vaccines.

show abstract

Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits

Cited by 3 publications

References 61 publications

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report

Production and Study of Immunochemical Properties of Stabilized Env Trimer of Recombinant Form CRF63_02A6 of HIV-1

mRNA-based HIV-1 vaccines

Contact Info

Product

Resources

About